Separation matrix and separation method

By using nonwoven polymer fiber membranes with covalent coupling of multimodal ligands in chromatography, the problems of low binding capacity and limited flow rate of chromatography are solved, and efficient biomacromolecule separation is achieved, suitable for industrial-scale Biotherapeutic processing.

CN115397552BActive Publication Date: 2024-12-06CYTIVA BIOPROCESS R&D AB
View PDF 12 Cites 0 Cited by

Patent Information

Application Number
CN202180031403.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-04-28
Filing Date
2021-04-16
Publication Date
2024-12-06
Estimated Expiration
2041-04-16

AI Technical Summary

Technical Problem

The existing chromatography has problems of low binding capacity, limited flow rate and mechanical instability in the separation of biomacromolecules, resulting in insufficient production capacity and difficult to meet the high flow rate requirements of industrial scale.

Method used

Nonwoven polymer fiber membranes covalently coupled with multiple multimodal ligands are used as separation matrix, and their high selectivity interacts with biomacromolecules to achieve rapid biomacromolecules separation and multi-step binding-elution The circulation method improves separation efficiency.

Benefits of technology

It significantly improves the selectivity and production capacity of biological macromolecules separation, can maintain high binding capacity at high flow rates, is suitable for industrial-scale biotherapeutic processing, and reduces the amount of adsorbent used and separation time.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115397552B_ABST
    Figure CN115397552B_ABST
Patent Text Reader

Abstract

The present invention discloses a separation matrix comprising a plurality of multimodal ligands covalently coupled to a support, wherein the support is a membrane comprising nonwoven polymer fibers, and wherein the ligands are capable of interacting with target biomacromolecules. In addition, the present invention discloses a separation method using the separation matrix.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to separation matrices and, more particularly, to adsorptive membrane matrices having multimodal ligands. Background Art

[0002] The biotechnology market is the fastest growing segment of the world pharmaceutical market, accounting for 20% ($153bn) of all market sales in 2012. The increase from a 10% market share in 2002 is set to grow by 41% between 2012 and 2018, from $153bn to $215bn. With approximately 200 monoclonal antibody (mAb) products currently on the market and over 1,000 in clinical trials, the need for technological advances in this area is evident. Over the past few decades, typical fermentation titers of biomolecules in industrial settings have grown from 0.5 g / L to approximately 3 g / L, with levels of up to 10 g / L believed to be achievable in the near future based on active advances in molecular biology. However, while downstream purification methods have also received some research and development, improvements in this area have not matched those in the upstream.

[0003] The manufacture of therapeutic proteins requires high purity to be achieved during processing so that the administered protein is essentially free of harmful contaminants. Currently, chromatography is the main method used to achieve high purity proteins on an industrial scale. From an economic perspective, heavy reliance on chromatography unit operations is key to the progress of downstream processing of biomolecules (e.g., mAbs). Chromatography accounts for up to 60% of biotherapeutic processing (Re-use of Protein A Resin: Fouling and Economics, BioPharm International, Vol. 28, No. 3, March 1, 2015, Anurag S. Rathore, Mili Pathak, Guijun Ma, Daniel G. Bracewell).

[0004] Such chromatographic separation includes when a liquid phase containing a target molecule and impurities is contacted with a solid phase, i) the target molecule and / or ii) one or more impurities bind to the solid phase. The interaction between the target molecule / impurity and the solid phase can be based on charge, hydrophobicity, affinity or a combination thereof.

[0005] Historically, conventional packed bed chromatography using porous beads is an extremely powerful separation tool. The porous nature of these beads creates a high surface area for binding target or impurities. This results in high capacity materials, meaning that less adsorbent material can be used. High capacity also increases the concentration achieved during separation, because more target may be bound per unit volume of adsorbent compared to the relative concentration of the loaded suspension. These aspects are critical for industrial scale processing, where several kilograms of material need to be purified from liquid volumes that can reach up to 20,000 L per batch. The typical binding capacity of porous beads is in the region of 35-120 mg / mL, depending on the functionality of the solid phase and the substance being bound.

[0006] In porous bead-based systems, the binding events between the target molecule / impurity and the solid phase depend on diffusion into the porous beads. Therefore, there is a strong correlation between residence time and flow rate in porous bead-based systems. Therefore, the binding capacity decreases with decreasing residence time. This in turn is accompanied by a rapid decrease in capacity, where times of less than 2 minutes are used in porous bead-based systems. The high flow rates required for short residence times may also be incompatible with porous beads, particularly at manufacturing scales where many liters of bead suspension are packed into a column. Here, the mechanical instability of the porous beads can lead to compression or collapse events, which in turn lead to an uneven column bed.

[0007] Since flow rate affects residence time, it is critical to maximize the amount of target that can be bound to the solid phase per unit time. This allows for the use of smaller adsorbent volumes and / or separations to be performed in shorter times. This metric can be defined as grams bound per unit volume per unit time (mg / mL / min). The typical binding capacity and residence time of the porous beads discussed above result in a total throughput of about 10-120 mg / mL / min for a single column porous bead system.

[0008] As an alternative to systems based on porous beads, monoliths or membranes can be used. The flow through such materials is convective rather than diffusive, and therefore their binding capacity is far less sensitive to flow than systems based on porous beads. These materials can be operated at much higher flow rates than materials based on porous beads, with typical residence times on the order of 0.2-0.5 minutes. However, under dynamic flow, the typical binding capacity for monoliths (10-20 mg / mL) and membranes (7.5-29 mg / mL) at a target 10% penetration is lower than that of porous beads (Gottschalk, U. (2008). Biotechnol Prog, 24 (3), 496-503). By utilizing higher flow rates, the poor binding capacity of monoliths and membrane materials (compared with materials based on porous beads) can be compensated to a certain extent.

[0009] The typical binding capacities and residence times of the monoliths and membranes discussed above result in a total throughput of binding events for the monolith and membrane system of about 10-145 mg / mL / min.

[0010] There is a need for chromatography materials that have the high binding capacity associated with porous bead-based materials and the higher flow rates achievable with monolithic / membrane materials. Such materials would provide high capacity at high flow rates to achieve maximum throughput (mg / mL / min). Summary of the invention

[0011] One aspect of the present invention is to provide a separation matrix that provides rapid biomacromolecule separation with high selectivity. This is achieved using a matrix having a plurality of multimodal ligands covalently coupled to a support, wherein the support is a membrane comprising nonwoven polymer fibers, and wherein the ligands are capable of interacting with the target biomacromolecule.

[0012] A second aspect of the present invention is to provide a rapid flow separation method with high selectivity. This is achieved using a method for recovering purified biomacromolecules from a load fluid comprising one or more impurities, comprising the following steps:

[0013] a) passing the load fluid through a separation matrix as discussed above; and

[0014] b) recovering said purified biomacromolecule in said matrix effluent during said load cycle and optionally during any substantially isocratic wash.

[0015] A third aspect of the present invention is to provide a fast binding-elution separation method with high selectivity. This is achieved using a method for recovering purified biomacromolecules from a load fluid comprising one or more impurities, which comprises the following steps:

[0016] a) passing the load fluid through a separation matrix as discussed above;

[0017] b) optionally passing a wash fluid through the separation matrix;

[0018] c) passing an eluent through the separation matrix;

[0019] d) recovering the purified biomacromolecule in the eluate after passing through the separation matrix; and

[0020] e) passing a regeneration fluid through the separation matrix.

[0021] Further suitable embodiments of the invention are described in the dependent claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 Schematic diagram showing a chromatography medium of the present invention.

[0023] Figure 2 Schematic diagram showing a chromatography medium of the present invention.

[0024] definition

[0025] The terms "antibody" and "immunoglobulin" are used interchangeably herein and are understood to also include fragments of antibodies, fusion proteins comprising antibodies or antibody fragments, and conjugates comprising antibodies or antibody fragments.

[0026] The terms "Fc binding polypeptide" and "Fc binding protein" refer to a polypeptide or protein, respectively, that is capable of binding to the crystallizable portion (Fc) of an antibody, and include, for example, Protein A and Protein G, or any fragment or fusion protein thereof that retains the binding property.

[0027] The term "spacer" refers herein to an element that links a ligand to a support.

[0028] As used herein, the terms "comprises," "comprising," "containing," "having," and the like may have the meanings ascribed to them in U.S. patent law, and may refer to "includes," "including," and the like; "consisting essentially of" or "consists essentially of" likewise have the meanings ascribed to them in U.S. patent law, and the terms are open-ended, allowing for more than those listed, as long as the basic or novel features of those listed are not altered by the presence of more than those listed, but excluding prior art embodiments. DETAILED DESCRIPTION

[0029] In one aspect, the present invention discloses a separation matrix comprising a plurality of multimodal ligands covalently coupled to a support. The support is a membrane comprising nonwoven polymer fibers, which may suitably be polymer nanofibers, such as cellulose nanofibers, and the multimodal ligands are capable of interacting with target biomacromolecules (e.g., proteins, protein conjugates, nucleic acids, viral particles, or virus-like particles). See below for further details on the support and (nano)fibers. The ligand is a chemical moiety covalently bound to the support, directly bound to the fiber surface, or bound to a polymer grafted on the fiber surface, as discussed below. The ligand may further be covalently bound to the fiber surface or the grafted polymer via a spacer. The spacer is well known in the field of separation matrices and may typically be an organic group having one or more carbon atoms (e.g., 1-10 carbon atoms) that connects the ligand to the fiber surface or polymer. The ligands are multimodal, which means that they are capable of interacting with the target biomacromolecule via at least two types of interactions, resulting in a higher degree of selectivity than can be achieved with a single type of interaction. Therefore, the ligand can have at least two of the following different functionalities: positive charge, negative charge, hydrophobic group, aromatic group capable of π-π interaction or cation-π interaction, hydrogen bond donor, hydrogen bond acceptor, electron donor and electron acceptor. Preferred combinations include positive charge + hydrophobic group, positive charge + aromatic group, negative charge + hydrophobic group, negative charge + aromatic group and negative charge + electron donor. The amount of the ligand can be suitable so that the ligand density of the separation matrix is ​​100-2000 μmol ligand / g dry separation matrix. This provides a high binding capacity for the target biomolecule combined with high selectivity.

[0030] Ligand

[0031] In some embodiments, the multimodal ligand comprises a multimodal anion exchange ligand, ie, a ligand having a positive charge and a hydrophobic group and / or an aromatic group. The multimodal anion exchange ligand may be, for example, a ligand having the structure

[0032] R1-L1-N(R3)-L2-R2,

[0033] It is coupled to the support via the nitrogen so that the tertiary amine nitrogen after coupling is a quaternary ammonium group, wherein:

[0034] R1 is a five-membered or six-membered substituted or unsubstituted aromatic or aliphatic ring structure, a hydroxyethyl group or a C1-C4 alkyl group;

[0035] L1 is a methylene group or a covalent bond;

[0036] R2 is a five-membered or six-membered substituted or unsubstituted aromatic or aliphatic ring structure;

[0037] L2 is a methylene group or a covalent bond;

[0038] R3 is methyl.

[0039] The ligand may in particular comprise an N-benzyl-N-methylethanolamine ligand coupled to the support via nitrogen, wherein in this case R1 is a hydroxyethyl group, L1 is a covalent bond, R3 is a methyl group, L2 is a methylene group, and R2 is an unsubstituted benzene ring. Alternatively, the ligand may comprise a) N,N-dimethylbenzylamine (R1 is a methyl group, L1 is a covalent bond, R3 is a methyl group, L2 is a methylene group, and R2 is an unsubstituted benzene ring), b) 2-(N-(cyclohexylmethyl)-N-methylamino)ethanol (R1 is a hydroxyethyl group, L1 is a covalent bond, R3 is a methyl group, L2 is a methylene group, and R2 is an unsubstituted cyclohexyl ring), c) 2-(N-(4-(trifluoromethyl)benzyl)-N-methylamino)ethanol (R1 is a hydroxyethyl group, L1 is a covalent bond, R3 is a methyl group, L2 is a methylene group, and R2 is an unsubstituted cyclohexyl ring). covalent bond, R3 is methyl, L2 is methylene, and R2 is p-trifluoromethylphenyl), d) 2-(N-(3,4,5-(trimethoxy)benzyl)-N-methylamino)ethanol (R1 is hydroxyethyl, L1 is a covalent bond, R3 is methyl, L2 is methylene, and R2 is trimethoxyphenyl) or e) N-benzyl-N-methyl(thiophen-2-yl)methanamine (R1 is a thiophene ring, L1 is a methylene, R3 is a methyl, L2 is a methylene, and R2 is an unsubstituted benzene ring). See also US20150299248, which is incorporated herein by reference in its entirety.

[0040] Alternatively, the multimodal anion exchange ligand may comprise a ligand having the structure

[0041] N(R6,R7)-R8-L3-Ar

[0042] It is coupled to the support via nitrogen N, wherein:

[0043] R6 and R7 are independently hydrogen, 1-6 carbon alkyl or hydroxyethyl;

[0044] R8 is 1-6 carbon alkyl or cycloalkyl or ethoxy;

[0045] L3 is a covalent bond, NR9, O or S, wherein R9 is a 1-6 carbon alkyl group;

[0046] Ar is a substituted or unsubstituted aromatic or heteroaromatic ring.

[0047] Examples of such ligands are, for example, N-phenyl-ethylenediamine, 2-phenoxyethylamine, N,N-dimethyl-2-phenoxy-ethan-1-amine, N,N-dimethyl-3-phenoxy-propan-1-amine, N,N-dimethyl-2-(2-phenoxyethoxy)ethan-1-amine, 2-(methyl(2-phenoxyethyl)amino)ethan-1-ol, 2-(3,5-dimethylphenoxy)-N,N-dimethylethan-1-amine, 2-([1,1'-biphenyl]-4-yloxy)-N,N-dimethyl 2-(4-ethylphenoxy)-N,N-dimethylethan-1-amine, 2-(4-isopropylphenoxy)-N,N-dimethylethan-1-amine, 2-(4-fluorophenoxy)-N,N-dimethylethan-1-amine, 2-(2,5-difluorophenoxy)-N,N-dimethylethan-1-amine, 2-(3-fluorophenoxy)-N,N-dimethylethan-1-amine, 2-(3,5-difluorophenoxy)-N,N-dimethylethan-1-amine , N-dimethylethane-1-amine, 2-(3,5-difluorophenoxy)-N,N-dimethylpropan-1-amine, 2-(3,4-difluorophenoxy)-N,N-dimethylethane-1-amine, 2-(3,4,5-trifluorophenoxy)-N,N-dimethylethane-1-amine, 2-(4-(tert-butyl)phenoxy)-N,N-dimethylethane-1-amine, N,N-dimethyl-2-(naphthalen-1-yloxy)ethane-1-amine, N,N-dimethyl-2-(perfluorophenoxy)ethane-1-amine, N , N-dimethyl-2-(pyridin-4-yloxy)ethyl-1-amine, N,N-dimethyl-2-(pyridin-3-yloxy)ethyl-1-amine, 2-((2,6-dimethylpyridin-4-yl)oxy)-N,N-dimethylethyl-1-amine, N,N-dimethyl-3-(pyridin-4-yloxy)propan-1-amine, N,N-dimethyl-3-phenoxycyclobutyl-1-amine, N,N-dimethyl-3-phenoxycyclopentyl-1-amine and N,N-dimethyl-3-phenoxycyclohexyl-1-amine. See also WO2019173731 and US9669402, which are incorporated herein by reference in their entirety.

[0048] In certain embodiments, the multimodal ligand comprises a multimodal cation exchange ligand, i.e., a ligand having a negative charge and a hydrophobic group and / or an aromatic group. The multimodal cation exchange ligand may, for example, comprise a ligand having the structure S-R4(COOH)-N(H)-C(O)-R5

[0049] It is coupled to the support via sulfur, wherein:

[0050] R4 is C2-C6 alkylene; and

[0051] R5 is a five-membered or six-membered substituted or unsubstituted aromatic or aliphatic ring structure.

[0052] The ligand may particularly comprise a ligand having the structure

[0053]

[0054] It is coupled to the support via sulfur.

[0055] Alternatively, the multimodal cation exchange ligand may comprise a copolymer chain comprising units derived from

[0056] a) a first monomer of the structure CH2═CH-L4-X1, wherein L4 is a covalent bond or an alkyl ether or hydroxy-substituted alkyl ether chain containing 2 to 6 carbon atoms, and X1 is a sulfonate or phosphonate group, and

[0057] b) a second uncharged vinyl amide monomer.

[0058] The copolymer chain can be, for example, a vinyl sulfonate-co-N-vinyl pyrrolidone copolymer chain, wherein L4 is a covalent bond, X1 is a sulfonate, and the vinyl amide is N-vinyl pyrrolidone. Alternatively, the copolymer chain can be a vinyl phosphonate-co-N-vinyl pyrrolidone copolymer chain (X1 is a phosphonate) or a vinyl sulfonate-co-N-vinyl caprolactam chain (the vinyl amide is N-vinyl caprolactam).

[0059] Alternatively, the multimodal cation exchange ligand may comprise a ligand having the structure

[0060] NH-Ph-(CH2) n -X2-(CH2) n -COO -

[0061] It is coupled to the support via nitrogen N, wherein:

[0062] Ph is a benzene ring, in which the NH group is in the ortho, meta or para position;

[0063] n is 0, 1 or 2;

[0064] m is 1, 2, 3, 4 or 5;

[0065] X2 is selected from the group consisting of a covalent bond, S, C(O)NH, NHC(O), C(O)NHCH2C(O)NH and SO2.

[0066] Examples of such ligands are, for example, p-NH-Ph-CH2C(O)NHCH2COO - ,p-NH-Ph-C(O)NHCH2C(O)NHCH2COO - 、o-NH-Ph-C(O)NHCH2COO -、p-NH-Ph-CH2SCH2COO - 、o-NH-Ph-CH2SCH2COO - 、p-NH-Ph-CH2SO2CH2COO - 、p-NH-Ph-CH2COO - and p-NH-Ph-(CH2)3COO - See also US2015258539, which is incorporated herein by reference in its entirety.

[0067] Additionally, the multimodal cation exchange ligand may comprise a ligand having the structure

[0068] R9CH(NH2)COOH

[0069] It is coupled to the support via nitrogen N, wherein:

[0070] R9 is an aromatic group or a C5-C7 nonionic aliphatic group.

[0071] Examples of such ligands are, for example, phenylalanine, tryptophan, leucine, isoleucine and norleucine.See also US8530698, which is incorporated herein by reference in its entirety.

[0072] In some embodiments, the multimodal ligand comprises a metal chelating ligand, i.e., a ligand having at least two types of groups that form a coordination bond with a metal ion, such as an electron donor group (e.g., a tertiary amine) and a negatively charged group (e.g., a carboxylate group). The metal chelating ligand may particularly comprise a ligand having at least three carboxyl groups and at least one tertiary amine (e.g., at least two tertiary amines). An example of such a ligand is a ligand having the structure

[0073]

[0074] It is coupled to the support via the amide nitrogen. Another example is a ligand having the structure

[0075]

[0076] It is coupled to the support via sulfur.

[0077] Still further examples include ligands having the following structures: NH2(CH2)4CH(COOH)N(CH2COOH)2 coupled to the support via the terminal nitrogen and HOOCCH2NHCH2CH2CN(CH2COOH)2 coupled to the support via the secondary amine nitrogen.

[0078] The separation matrix with metal chelating ligands may further comprise transition metal ions, such as Ni bound to the ligands. 2+ Ion, Co2+ Cu 2+ ions. These ions can bind to proteins, especially those with polyhistidine tags, and can be used to selectively separate these proteins from complex mixtures.

[0079] Polymer Nanofibers

[0080] The separation matrix of the present invention is formed by polymer fiber / nanofiber supports. Each support is formed by one or more polymer fibers / nanofibers.

[0081] The polymer fibers / nanofibers are typically electrospun polymer nanofibers. Such electrospun polymer nanofibers are well known to those skilled in the art, and their optimal production conditions can be found, for example, in O.Hardick et al., J.Mater.Sci.46 (2011) 3890, the entire contents of which are incorporated herein by reference. The method of the present invention typically includes an initial step of electrospinning a polymer to produce one or more polymer nanofibers. This can include electrospinning a polymer to produce one or more nonwoven sheets or layers, each comprising one or more polymer nanofibers. Suitably, one or more sheets or one or more layers (10) each contain a plurality of nanofiber-nanofiber fusion points (20), such as in Figure 1 Intra-layer fusion points between individual nanofibers (30) at their junctions provide mechanical stability to the sheet / layer and reduce the risk of nanofibers falling into the liquid during use. Fusion points can be suitably achieved by controlling the temperature during the electrospinning process so that the deposited nanofibers contact each other before solidification. It may be particularly advantageous to electrospin a polymer solution, in which case the formed fibers solidify by evaporation of the solvent, providing sufficient time for the formation of intra-layer fusion points before solidification.

[0082] The polymer fiber / nanofiber used for the present invention usually has an average diameter of 10nm to 1000nm. For some applications, the polymer nanofiber with an average diameter of 200nm to 800nm ​​is suitable. The polymer fiber / nanofiber with an average diameter of 200nm to 400nm may be suitable for certain applications. The length of the polymer fiber / nanofiber used for the present invention is not particularly limited. Therefore, conventional electrostatic spinning methods can produce polymer nanofibers with a length of hundreds of meters or even thousands of meters. However, usually, the length of one or more polymer fibers / nanofiber is at most 10km, preferably 10m to 10km. The polymer fiber / nanofiber can be suitably a monofilament nanofiber, and can for example have a circular, elliptical or substantially circular / elliptical cross section.

[0083] One or more polymer fibers / nanofibers are provided in the form of one or more nonwoven sheets, each of which comprises one or more polymer fibers / nanofibers. Therefore, support is usually formed by one or more nonwoven sheets, and each sheet comprises one or more polymer fibers / nanofibers. The nonwoven sheet comprising one or more polymer fibers / nanofibers is a pad of one or more polymer nanofibers, wherein each nanofiber is substantially randomly oriented, that is, it is not manufactured to make one or more nanofibers adopt a specific pattern. The nonwoven sheet comprising polymer fibers / nanofibers is usually provided by a known method, such as in O.Hardick et al., J.Mater.Sci.46 (2011) 3890 disclosed method. In some cases, the nonwoven sheet can be composed of a single polymer nanofiber. Alternatively, the nonwoven sheet can comprise two or more polymer nanofibers, such as 2,3,4,5,6,7,8,9 or 10 polymer nanofibers.

[0084] Nonwoven sheets usually have a surface density of 1-40 g / m 2 , preferably 5-25g / m 2 , in some cases 1-20 or 5-15 g / m 2 .

[0085] The nonwoven sheet typically has a thickness of 5-120 μm, preferably 10-100 μm, in some cases 50-90 μm, and in other cases 5-40, 10-30, or 15-25 μm.

[0086] There is no particular restriction on the polymer for producing the fiber / nanofiber used in the method for the present invention, as long as the polymer is suitable for chromatography application. Therefore, usually, polymer is a polymer suitable for use as a chromatography medium (i.e., adsorbent) in a chromatography method. Suitable polymers include polyamide (e.g., nylon), polyacrylic acid, polymethacrylic acid, polyacrylonitrile, polystyrene, polysulfone (e.g., polyethersulfone (PES)), polycaprolactone, collagen, chitosan, polyethylene oxide, agarose, agarose acetate, cellulose, cellulose acetate and combinations thereof. Preferred polyethersulfone (PES), cellulose, cellulose acetate and combinations thereof. In some cases, preferred cellulose, cellulose acetate and combinations thereof.

[0087] In some embodiments, the substrate comprises one or more fibers / nanofibers formed from different polymers. Thus, in this embodiment, the substrate comprises one or more different polymers. Typical polymers are as defined above.

[0088] Generally, the present invention relates to a functionalized cellulose separation matrix prepared from a support formed of one or more cellulose acetate fibers / nanofibers. Preferably, the preparation comprises providing a substrate formed of one or more nonwoven sheets or layers, each sheet or layer comprising one or more cellulose acetate nanofibers. Cellulose acetate is susceptible to electrospinning, typically from a solution of cellulose acetate in one or more organic solvents, and can be easily converted to cellulose after electrospinning. Therefore, preferably, the support is formed of one or more nonwoven sheets / layers, each sheet / layer comprising one or more electrospun cellulose acetate nanofibers.

[0089] Physical modification of fibers / nanofibers

[0090] In some preferred embodiments of the present invention, providing substrate is included before the grafting step, optionally in nonwoven sheet / layer, polymer nanofiber is physically modified. Specifically, physical modification can include heating and / or pressing polymer nanofiber / nonwoven sheet / layer, preferably heating and pressing polymer nanofiber / nonwoven sheet / layer. These steps improve the structural stability of the material. It is also possible to change the pressing and heating conditions to change the thickness and / or porosity of the resulting material.

[0091] Multiple nonwoven sheets using polymer nanofibers can prepare thicker materials, which have larger adsorption capacity (once grafted and functionalized). Therefore, providing a support generally includes providing two or more nonwoven sheets / layers, described sheets / layers are stacked one on top of another, each described sheet comprises one or more polymer nanofibers, and the stacking of heating and pressing sheets / layers simultaneously is to fuse the contact point between the nanofibers of adjacent sheets / layers, producing interlayer fusion point. In the case of cellulose separation matrix, providing a support generally includes providing two or more nonwoven sheets / layers, described sheets / layers are stacked one on top of another or folded, each described sheet / layer comprises one or more cellulose acetate nanofibers, and the stacking of heating and pressing sheets / layers simultaneously is to fuse the contact point between the nanofibers of adjacent sheets. Therefore, functionalized separation matrix can be the stacking of multiple nonwoven polymer nanofiber layers, which has multiple interlayer nanofiber-nanofiber fusion points that make at least two layers bonded to each other.

[0092] Preferred processing conditions for pressing and heating polymer nanofibers / nonwoven sheets can be found in US20160288089 and WO 2015 / 052465, the entire contents of which are incorporated herein by reference.

[0093] Grafted nanofiber substrate

[0094] The preparation of the matrix of the present invention may include a grafting step which generally comprises grafting one or more neutral polymer chains from a support as provided above.

[0095] Grafting one or more neutral polymer chains from a substrate generally comprises growing one or more polymer chains from one or more functional groups present on the substrate, optionally in the presence of one or more catalysts. Thus, generally, the substrate comprises one or more functional groups, preferably one or more functional groups from which polymer chains can be grown. Growing polymer chains from one or more functional groups refers to building polymers at one or more functional groups from separate monomer building blocks. Thus, the grafting step generally comprises growing polymer chains directly from the substrate, rather than bonding preformed polymer chains to the substrate. However, bonding preformed polymers (e.g., polyglycidol) is also an alternative. Thus, as polymerization proceeds, a single monomer is added to the end of a growing polymer chain anchored to the substrate at a distance. The polymer coating will then comprise polymer molecules covalently bound to the substrate at a single point. The polymer molecules may be linear or branched, and even hyperbranched, in which case greater than 50% of the monomer residues are branching points or terminal monomers. Growing polymer chains directly from the substrate enables control of the structure of the polymer coating, particularly using a polymerization strategy in which all polymers grow simultaneously at a uniform rate. This enables the formation of a dense and well-defined polymer coating. Therefore, when the substrate is one or more layers of polymer nanofibers fused together at their junctions, a thin coating with clear boundaries will be formed, covering the core nanofibers and the fusion points between the individual nanofibers. The coating can be a conformal coating, that is, following the contours of the nanofibers and the fusion points. The thickness of the coating can be, for example, such that the average diameter of the coated nanofibers is 100-1000nm, such as 100-700nm or 200-700nm. The average diameter of the uncoated nanofibers can then be, for example, 100-800nm, such as 100-600nm. The average pore size of one or more layers can be, for example, 200-800nm, and the pore volume fraction can be, for example, 50-90%, such as 60-80%. The average pore size and average fiber diameter can be calculated from the SEM image of the layer, and the pore volume fraction can be calculated from the total volume (thickness multiplied by the cross-sectional area) of the layer or substrate and the specific gravity of the nanofibers. A specific example of pore volume calculation for a representative multilayer cellulose acetate nanofiber disk is: a disk diameter of 32 mm and a disk thickness of 0.44 mm gives 0.354 cm 3 The total volume of the disk is 0.165 g, of which the specific gravity of cellulose acetate is 1.31 g / cm 3 The volume of cellulose acetate is 0.126 cm 3 Therefore, the pore volume fraction is (0.354-0.126) / 0.354=64%.

[0096] The pore structure of the layer is important for performance because a delicate balance between high dynamic binding capacity (large accessible surface and short diffusion paths) and low back pressure (large pores and high pore volume fraction) needs to be met. Grafted nanofiber layers are uniquely suited to meet this balance, they have small fiber diameters and high pore volume fractions. A particularly good combination is achieved when the layer has pore sizes as obtained by capillary flow porosimetry using a perfluoropolyether wetting liquid: a bubble point pore size of 0.9-1.2 μm, such as 1.0-1.2 μm; a minimum pore size of 0.2-0.4 μm and / or a mean flow pore (MFP) pore size of 0.3-0.5 μm. The measurements should be performed as detailed in the analytical methods below.

[0097] For good flow properties, it is advantageous if the open-porous structure of the support is maintained after the grafting process. Figure 2 The first side (40) and the second side (50) described in the method are fluidly connected to each other through an open and three-dimensionally connected pore structure (60) formed by the gaps (interstitial volume) between the grafted polymer nanofibers. The pore structure is preferably free of or substantially free of grafted polymer or any homopolymers accidentally formed during the grafting process. This can be achieved by limiting the amount of monomer added during grafting, and any polymer that does not block the pore structure can be easily checked by measuring the flow rate and / or by observing the pore structure by electron microscopy. The graft polymerization method provides the unique possibility of introducing functionalized polymers, which increase the binding capacity without blocking the pore structure.

[0098] The advantage of the grafted layer of the present invention, especially compared with the membrane coated with hydrogel, is that the back pressure is basically independent of the buffer conductivity and pH. This is due to the absence of significant swelling / shrinking phenomena and can be expressed as that when an aqueous buffer of pH 5-8 is passed through the functionalized separation matrix with a residence time of 0.4 s, the pressure drop across the functionalized matrix varies by less than 0.07 MPa / mm bed height (medium thickness) when the conductivity of the buffer varies in the interval of 3-90 mS / cm (as measured at 22° C.). 3 mS / cm corresponds to 20 mM acetate or Tris buffer, while 90 mS / cm corresponds to the same buffer with about 1 M NaCl added.

[0099] In the present invention, grafting may include reacting multiple compounds and / or their enantiomers or derivatives.

[0100] Most preferably, grafting comprises bonding a support having one or more functional groups from which a polymer can grow to a support of the formula and / or its enantiomers and / or its derivatives and / or its enantiomers and / or diastereomers of formula (I):

[0101]

[0102] In embodiments where the support is formed of nanofibers formed of different polymers, each different type of polymer nanofiber can be grafted with a different polymer in the grafting step. This may, for example, result from different functional groups present on the different polymer nanofibers. Alternatively, the same polymer can be grafted onto each different type of polymer nanofiber in the support.

[0103] Typical functional groups include hydroxyl, amino and carboxyl. In the case where the support is formed from one or more cellulose or cellulose acetate nanofibers, the functional group is typically hydroxyl.

[0104] In a particularly preferred embodiment, the functional groups are hydroxyl groups. In this particularly preferred embodiment, the grafting is generally carried out under conditions which additionally deprotect the hydroxyl groups on the substrate in the same step.

[0105] Deprotection of the functional groups is usually carried out so that the functional groups can have one or more polymer chains growing from them. For example, when the separation matrix is ​​a cellulose separation matrix, a cellulose acetate support is usually provided, and before the grafting step, the cellulose acetate is treated to convert it into cellulose. This includes the deprotection of acetylated hydroxyls to obtain hydroxyls. The conversion of cellulose acetate to cellulose usually uses an aqueous base (preferably NaOH in water: ethanol (more preferably water: ethanol 2: 1)) for a period of more than 12 hours, such as 12-36 hours. Depending on the conditions, the conversion (saponification) can be complete or partial, resulting in a certain content of residual acetate groups. Preferably, the conversion is complete, but a residual acetate content of up to about 5 or 10 μmol / g of the dried support can be tolerated.

[0106] Alternatively, when the chromatography medium is a cellulose separation matrix, a cellulose acetate support is provided and in the grafting step (ii) the cellulose acetate is converted to cellulose and the cellulose is subsequently grafted with a cellulose matrix of formula The grafting step (ii) is carried out under conditions of reacting both of the plurality of compounds of formula (I) and / or its enantiomers and / or its derivatives and / or its enantiomers and / or diastereomers thereof to produce grafted polymer chains. In such an embodiment, the grafting step (ii) is typically carried out in the presence of an aqueous base (preferably NaOH or KOH (more preferably KOH) in water or water: ethanol (preferably in water)) for a period of 4-6 hours.

[0107] When the separation matrix is ​​a cellulosic separation matrix, the matrix is ​​typically prepared as follows:

[0108] (i) providing a support formed of one or more cellulose acetate nanofibers, treating the cellulose acetate to convert it into cellulose,

[0109] (ii) grafting one or more neutral polymer chains from the resulting cellulose support, and

[0110] (iii) contacting the grafted product with an agent which functionalizes the product of step (ii) into a separation matrix.

[0111] Alternatively, the matrix can be prepared as follows:

[0112] (i) providing a support formed of one or more cellulose acetate nanofibers,

[0113] (ii) subjecting the support to conditions whereby cellulose acetate is converted to cellulose and one or more neutral polymer chains are subsequently grafted onto the resulting cellulose support, and

[0114] (iii) contacting the grafted product with an agent which functionalizes the product of step (ii) into a separation matrix.

[0115] Methods for increasing the number and / or density of functional groups on a substrate are known to the skilled person.

[0116] When one or more functional groups are introduced into the support, the support is treated between steps (i) and (ii) and, in a further step (ia), the functional groups present on the support are modified to introduce functional groups from which one or more polymer chains can be grown, followed by step (ii) of growing polymer chains from the support thus modified.

[0117] In embodiments involving polymerization of glycidol, the support is typically treated between steps (i) and (ii) to deprotect any functional groups on the support.

[0118] The one or more polymer chains grafted to the support are suitably neutral. The polymer chains do not contain any groups that would be considered by those skilled in the art to be charged groups (e.g., the types of charged groups discussed below). Typically, the polymer chains grafted to the substrate in step (ii) do not contain any charged groups as defined herein.

[0119] The neutrality of a polymer can be evaluated by whether the polymer contains any groups that are ionizable (i.e., protonated or deprotonated) at a substantially neutral pH (e.g., pH 6-8, typically pH 6.5-7.5, typically pH 6.75-7.25, or about pH 7). Typically, a neutral polymer contains substantially no acidic or basic centers, i.e., substantially no functional groups that are protonated or deprotonated at pH 6-8 (typically pH 6.5-7.5, typically pH 6.75-7.25, or about pH 7). This can be determined by a skilled artisan by assays typical in the art. Typical procedures for assessing acidity and basicity and their theoretical aspects are discussed in "Acidity and basicity of solids: Theory, assessment and utility", edited by J. Fraisard and L. Petrakis, NATO ASI Series C, Vol. 444, Kluwer Academic Publishers, Dordrecht, Boston and London, 1994, especially on page 513, the entire contents of which are incorporated herein by reference. "Substantially" as used herein means less than 1 mol%, preferably less than 0.1 mol%, even more preferably less than 0.01 mol%, or even less than 0.001 mol%.

[0120] As described above, the grafting step (ii) may comprise bonding a substrate having one or more functional groups from which a polymer can grow to a substrate of formula reacting multiple compounds and / or their enantiomers.

[0121] Glycidol polymerization is a technique known to those skilled in the art. Glycidol polymerization does not generally require the presence of a catalyst. However, the polymerization may optionally be carried out in the presence of one or more suitable catalysts. In such embodiments, chemical or biological catalysts are generally used. Glycidol polymerization is generally carried out in an aqueous environment under mild alkaline conditions. Generally, glycidol polymerization is carried out at room temperature for greater than about 5 hours, for example, about 16 hours. After the glycidol polymerization, the grafted product is generally washed in water and then with a weak acid.

[0122] Glycidol polymerization comprises polymerizing glycidol and / or glycidol derivatives from one or more functional groups present on the substrate as defined herein. Typically, those functional groups are hydroxyl groups. Thus, typically, step (ii) comprises polymerizing a glycidol and / or glycidol derivative from one or more functional groups present on the substrate as defined herein. Typically, those functional groups are hydroxyl groups. and its enantiomers and / or its derivatives and / or its enantiomers and / or diastereomers are reacted with one or more hydroxyl groups present on the nanofiber substrate. Preferably, step (ii) comprises reacting a plurality of compounds of formula The plurality of compounds and their enantiomers react with one or more hydroxyl groups present on the nanofiber substrate.

[0123] Glycidol polymerization inevitably leads to branching of the polymer chain, producing a "bush" structure. Thus, typically, one or more polymer chains are branched, and as discussed above, may be hyperbranched. The different types of monomer residues in glycidol polymers are: triethers of glycerol (branch points), 1,2-diethers of glycerol (linear), and 1- or 2-monoethers of glycerol (terminal). In many cases, triether and monoether residues predominate, producing hyperbranched polymers.

[0124] In a second aspect, the present invention discloses a method for recovering a purified biomacromolecule from a load fluid comprising one or more impurities, comprising the steps of:

[0125] a) passing a load fluid through a separation matrix as discussed above; and

[0126] b) recovering the purified biomacromolecule in the matrix effluent during the load cycle and optionally during any substantially isocratic wash.

[0127] This flow-through method allows the rapid removal of adsorbed contaminants from non-bound or very weakly bound biomacromolecules. If the amount of contaminants is low (e.g., after the aforementioned affinity chromatography step), a large amount of biomacromolecules can be purified without any capacity problems. A typical example is the removal of aggregates and / or residual host cell proteins from immunoglobulins (e.g., monoclonal antibodies) using a separation matrix with multimodal anion exchange ligands as discussed above after a Protein A or Protein L affinity chromatography step. Advantageously, the affinity chromatography step can be performed on a separation matrix comprising a plurality of affinity ligands (e.g., Protein A or Protein L ligands) covalently coupled to a separation matrix comprising nonwoven polymer (e.g., cellulose) fibers (e.g., Fibro TM PrismA (Cytiva)) support membrane.

[0128] In a third aspect, the present invention discloses a method for recovering a purified biomacromolecule from a load fluid comprising one or more impurities, comprising the steps of:

[0129] a) passing a load fluid through a separation matrix as discussed above;

[0130] b) optionally passing a wash fluid through the separation matrix;

[0131] c) passing the eluent through a separation matrix;

[0132] d) recovering the purified biomacromolecule in an eluate after passing through a separation matrix; and

[0133] e) passing a regeneration fluid through the separation matrix.

[0134] This bind-elute method allows for efficient removal of adsorbed and / or non-adsorbed contaminants from bound biomacromolecules (e.g., target proteins). A typical example is the removal of aggregates and / or residual host cell proteins from immunoglobulins (e.g., monoclonal antibodies) using a separation matrix with multimodal cation exchange ligands as discussed above after a Protein A or Protein L affinity chromatography step. Advantageously, the affinity chromatography step can be performed on a separation matrix comprising a plurality of affinity ligands (e.g., Protein A or Protein L ligands) covalently coupled to a separation matrix comprising nonwoven polymer (e.g., cellulose) fibers (e.g., Fibro TM PrismA (Cytiva)) support membrane.

[0135] Another example is the above-discussed combination of a metal chelating ligand and a transition metal ion (e.g. Ni 2+ ) separation matrix to purify his-tagged proteins from cell culture supernatants or lysates.

[0136] The above separation matrix allows very fast separation cycles, and it is advantageous if steps a)-e) are repeated several times, for example at least 10 times or at least 20 or 50 times. The cycle time for each sequence of steps a)-e) can then be less than 5 minutes, for example less than 3 minutes or less than 2 minutes, or 0.5-5 minutes or 1-3 minutes.

[0137] Example

[0138] Example 1

[0139] Prior to electrospinning, a cellulose acetate solution with a relative molecular weight of 29,000 g / mol was dissolved in a common solvent to produce fibers with a diameter in the range of 300-600 nm. Optimized conditions for nanofiber production can be found, for example, in O. Hardick et al., J. Mater. Sci. 46 (2011) 3890, the entire contents of which are incorporated herein by reference. Approximately 20 g / m 2 Sheets of material are stacked and subjected to a combination of heat and pressure.

[0140] The nanofibrous material was derivatized according to the protocol outlined below:

[0141]

[0142] Step (i): Saponification of cellulose acetate (CA) to regenerated cellulose (RC)

[0143]

[0144] The cellulose acetate sheet (0.44*32mm*150mm) obtained according to the method of Example 1 was placed in a large beaker containing 5L of a 0.075M solution of sodium hydroxide in 2:1 water:ethanol. The reaction mixture was stirred at room temperature for 48 hours. The material was then washed according to washing scheme A.

[0145] Washing Solution A

[0146] The reaction medium was replaced with an equal volume of deionized water and circulated for 1 hour. The rinse procedure was repeated once more. Finally, the material was treated with an equal volume of aqueous ethanol (2:1 H2O:EtOH) before removal from the reaction vessel.

[0147] Step (ii): Glycidol polymerization

[0148]

[0149] The material obtained from (i) was suspended in 1 L of 0.5 M NaOH. The reaction medium was circulated for 15 minutes before carefully adding different amounts of glycidol (15 mL, 30 mL, 60 mL, 120 mL, 180 mL) in one go. The reaction medium was circulated for 16 hours at room temperature and the material was subsequently washed according to washing scheme B.

[0150] Washing plan B

[0151] The reaction medium was replaced with an equal volume of deionized water and circulated for 1 hour. Thereafter, the wash medium was replaced with 0.01M HCl and circulated for 1 hour, followed by replacement with 0.001M HCl and circulated for 1 hour. Finally, the medium was replaced with a 2:1 mixture of H2O:EtOH and circulated for 1 hour. The derivatized nanofibers were then removed from the reaction vessel.

[0152] Example 2 - Glycidol-grafted DVS functionalized material

[0153] The nanofibrous material was derivatized according to the protocol outlined below:

[0154]

[0155] Step (i): Saponification of cellulose acetate (CA) to regenerated cellulose (RC)

[0156]

[0157] The cellulose acetate sheet (0.44*32mm*150mm) obtained according to the method of Example 1 was placed in a large beaker containing 5L of a 0.075M solution of sodium hydroxide in 2:1 water:ethanol. The reaction mixture was stirred at room temperature for 48 hours. The material was then washed according to washing scheme A.

[0158] Step (ii): Glycidol polymerization

[0159]

[0160] The material obtained from (i) is suspended in 1 L of 1 M NaOH. The reaction medium is circulated for 15 minutes before 180 mL of glycidol are added in one portion. The reaction medium is circulated at room temperature for 16 hours and the material is subsequently washed according to washing protocol B.

[0161] Step (iii): Derivatization with divinyl sulfone

[0162]

[0163] The material from (ii) is suspended in a solution of 550 mL H O and K dissolved therein CO (48.8 g, 0.35 mole) and 150 mL acetonitrile. Before dropwise addition of divinyl sulfone (100 ml, 0.86 mole), the reaction medium is circulated for 15 minutes, after which the reaction medium is recirculated for 1.5 hours. The material is then washed according to washing scheme C.

[0164] Washing Solution C

[0165] The reaction medium was replaced with an equal volume of a 1:1 mixture of warm (60°C) deionized water: acetone, which was circulated for 30 minutes. The washing procedure was repeated two more times. Finally, the medium was replaced with a 2:1 mixture of H2O:EtOH, which was circulated for 1 hour. The derivatized nanofibers were then removed from the reaction vessel.

[0166] Example 3 - Alternatives to Glycidol-Grafted DVS-Functionalized Materials

[0167] The nanofibrous material was derivatized according to the protocol outlined below:

[0168]

[0169] Step (i): Glycidol polymerization and saponification

[0170] Glycidol polymerization and saponification of CA nanofiber material was carried out by taking CA nanofiber material (0.11×80×50 mm) and suspending it in 1 L of deionized water. The solvent was circulated for 3 hours before being renewed with another 1 L of deionized water. After repeating this process 4 times, the nanofiber material was suspended in 350 ml of 1M KOH. The reaction medium was circulated for 60 minutes before carefully adding different amounts of glycidol (100 ml), where 25% of the glycidol was added at once and the rest was added dropwise within 90 minutes. The reaction medium was circulated for 4 hours at room temperature and the material was subsequently washed according to washing scheme B.

[0171] Step (ii): Derivatization with divinyl sulfone

[0172]

[0173] The material from (i) is suspended in a solution of 550 mL H O and K dissolved therein CO (48.8 g, 0.35 mole) and 150 mL acetonitrile. Before dropwise addition of divinyl sulfone (100 ml, 0.86 mole), the reaction medium is circulated for 15 minutes, after which the reaction medium is recirculated for 1.5 hours. The material is then washed according to washing scheme C.

[0174] Example 4 Multimodal anion exchange matrix with N-benzyl-N-methylethanolamine ligand

[0175] Step 1:

[0176] 50 cellulose acetate disks (32 mm diameter, 0.9 mm thickness) were washed with distilled water (4 x 600 ml). The washing solution was removed and replaced with 350 ml of 0.5 M KOH solution. The disks were treated with KOH solution with stirring for 10 minutes before adding 100 ml of glycidol. The reaction medium was stirred vigorously on the disks for 2 hours. Thereafter, the supernatant liquid was removed and the disks were washed with distilled water (4 x 600 ml) to obtain a pure glycidol grafted cellulose intermediate, which was used in the next step without further modification.

[0177] Step 2:

[0178] 25 disks were taken from step 1 and treated with 300 ml of 1 M KOH. After stirring the disks for 10 minutes, 30 ml of allyl glycidyl ether was added in one portion. The resulting mixture was stirred vigorously for 16 hours. Thereafter, the supernatant was decanted and the disks were washed with distilled water (4 x 600 ml). The neat allylated intermediate was used in the next step without further modification.

[0179] Step 3:

[0180] 25 disks were taken from step 2 and suspended in 500 ml H2O containing 37.5 g Na2CO3 and 150 ml acetonitrile. The mixture was stirred vigorously while 100 ml divinyl sulfone was added dropwise over 60 minutes. The reaction mixture was then stirred vigorously for 16 hours. Thereafter, the supernatant liquid was decanted and the disks were washed 3 times with 600 ml acetone:H2O (1:1) and washed with distilled water (1×600 ml). The clean intermediate was used in the next step without further modification.

[0181] Step 4:

[0182] 25 disks from step 3 were suspended in 500 ml of H2O:acetonitrile (1:3) solution with 12.5 g of N-bromosuccinimide dissolved therein. The mixture was stirred vigorously for 4 hours. Thereafter, the supernatant liquid was decanted and the disks were washed with copious amounts of distilled water (6 x 600 ml). The clean intermediate was used in the next step without further modification.

[0183] Step 5:

[0184] 18 g of N-benzyl-N-methylethanolamine was suspended in 30 ml of H2O, and 6 ml of acetone was added to the mixture. The pH of the solution was adjusted to pH 15 with 5N NaOH. Meanwhile, 25 disks from step 4 were placed individually in the wells of a 6-well plate. 2.5 ml of N-benzyl-N-methylethanolamine solution was added to each disk. The plate was gently agitated on an orbital shaker for 16 hours. Thereafter, the reaction mixture was removed and each disk was washed with distilled water (5×10 ml) to obtain the final product, a white fiber disk.

[0185] The disk was placed in a syringe filter assembly and the filter was filtered using a syringe filter from MabSelect TM The monoclonal IgG antibody eluate containing 160 ppm host cell protein (HCP) from a PrismA column (Cytiva, Sweden) was passed through the disk with a residence time of 1.2 seconds and the flow-through was collected. Aliquots of the eluate were pre-adjusted to different pH and conductivity levels. After passing through the disk, the antibody yield and residual HCP content in the flow-through are shown in Table 1:

[0186] Table 1. Results of flow-through tests using multimodal anion exchange ligands

[0187] pH Conductivity (mS / cm) Yield (%) HCP(ppm) 6.5 18 97 111 7.0 10 99 54 7.5 3.5 99 26

[0188] Example 5 Multimodal cation exchange matrix with N-benzoylamido-homocysteine ​​ligand

[0189] Step 1:

[0190] 50 cellulose acetate disks (32 mm diameter, 0.9 mm thickness) were washed with distilled water (4 x 600 ml). The washing solution was removed and replaced with 350 ml of 0.5 M KOH solution. The disks were treated with KOH solution with stirring for 10 minutes before adding 100 ml of glycidol. The reaction medium was stirred vigorously on the disks for 2 hours. Thereafter, the supernatant liquid was removed and the disks were washed with distilled water (4 x 600 ml) to obtain a pure glycidol grafted cellulose intermediate, which was used in the next step without further modification.

[0191] Step 2:

[0192] 25 disks were taken from step 2 and suspended in 500 ml H2O containing 37.5 g Na2CO3 and 150 ml acetonitrile. The mixture was stirred vigorously while 100 ml divinyl sulfone was added dropwise over 60 minutes. The reaction mixture was then stirred vigorously for 16 hours. Thereafter, the supernatant liquid was decanted and the disks were washed 3 times with 600 ml acetone:H2O (1:1) and washed with distilled water (1×600 ml). The clean intermediate was used in the next step without further modification.

[0193] Step 3:

[0194] The disks from step 2 were placed individually in the wells of a six-well plate. Meanwhile, the N-benzoyl-DL-homocysteine ​​thiolactone solution was placed in a round-bottom flask containing 27 ml of HO. Then 4 ml of 50% w / v NaOH solution was added and the mixture was heated to 40°C for 2 hours under stirring. Thereafter, the solution was cooled to ambient temperature. The pH of the solution was adjusted to 11.6 and 2.5 ml of the prepared solution was added directly to each disk in the 6-well plate. The plates were incubated at 60°C for 16 hours. Thereafter, the supernatant was decanted and the disks were washed with distilled water (5×10 ml) to obtain the final product, which was a white fibrous disk.

[0195] The dynamic IgG binding capacity (10% breakthrough) of the prototype at a 2.4 s residence time was analyzed with polyclonal IgG (Gammanorm, Octapharma) and monoclonal IgG antibodies. Capacity tests were performed on a single 25 mM perforated disk placed in a membrane holder, with 0.47 mg / ml IgG loaded on the disk in a 50 mM NaAc buffer (pH 5.0) with different NaCl concentrations.

[0196] Table 2. Capacity test results using multimodal cation exchange ligands

[0197]

[0198] Example 6 Multimodal Cation Exchange Matrix with Poly(vinyl sulfonate-co-N-vinyl pyrrolidone) Ligands

[0199] A 32 mm diameter disk (thickness 0.9 mm) of the glycidol-grafted DVS functionalized material prepared in Example 2 was placed in a flask. Then a given amount (see Table 3) of N-vinyl pyrrolidone (VP), sodium vinyl sulfonate (30% aqueous solution) (VSA) and 2,2'-azobis(2-methylpropionamidine) dihydrochloride (ADBA) initiator was added to each flask. The pH of the reaction mixture was set to 6-7 by adding diluted acetic acid. Water was then added to make the total weight of the solution 2.45 g. The reaction was carried out in a cell culture plate that was large enough to accommodate a membrane with a diameter of 32 mm. The plate was placed on a heated vibrating table and the table was set to 65°C. The grafting reaction lasted for 16 hours, and then the disk in the well plate was washed. The material was stored in a 0.2M sodium acetate solution. The dynamic IgG binding capacity (10% penetration) of the prototype at a residence time of 2.4 s was analyzed.

[0200] Capacity tests were performed on individual 25 mM perforated disks placed in a membrane holder, where the disks were loaded with 0.5 mg / ml polyclonal IgG (Gammanorm, Octapharma) in 50 mM NaAc buffer, pH 5.0.

[0201] Table 3 IgG capacity test results using multimodal cation exchange ligands

[0202]

[0203] Example 7 Metal Chelating Matrix with EDTA Ligand

[0204]

[0205] 1- Amination step

[0206] Three membrane sheets (such as the glycidol grafted DVS functionalized material prepared in Example 2) were wrapped around the mesh and then washed with 3×700 ml of water (20 minutes each wash) in a beaker to remove the 20% ethanol storage solution. The well-washed sheets around the mesh were transferred to a reactor (500 ml) and 700 ml of 25% ammonia was added and the reaction mixture was placed at 450° C. overnight. The sheets around the mesh were transferred to a beaker and washed with 3×700 ml of water (20 minutes each wash).

[0207] 2-Ligand coupling step

[0208] The three aminated sheets on the net from step 1 were washed in a beaker with 6×1 GV acetone, then transferred to a reactor and 700 ml acetone was added. 2.9 g diisopropylethylamine (DIPEA) was added to the reaction mixture and reacted for 5 minutes under stirring. 53 g EDTA dianhydride was added to the reaction mixture and the mixture was placed at 24-28° C. overnight. The sheets on the net were washed in a beaker with 3×1 GV acetone, then with 3×1 GV water, and then with GV 1M NaOH for 1 hour to hydrolyze excess unreacted EDTA. The sheets on the net were washed in a beaker with 6×1 GV water (20 minutes each wash).

[0209] The sheets from the ligand coupling step were placed in a plastic box and 100 mM NiSO4 solution was added to the box for 15 minutes at ambient temperature on a shaker. The color of the sheets changed from white to turquoise / blue.

[0210] Let the sheets characterize the binding capacity.

[0211] Example 8 Metal Chelating Matrix with N,N-Dicarboxymethyl-Homocysteine ​​Ligand

[0212]

[0213] Hydrolysis of N,N-dicarboxymethyl ethyl homocysteine ​​thiolactone

[0214] N,N-dicarboxymethylethyl ester homocysteine ​​thiolactone 0.293 g was added to 6.5 mL 1.05 M NaOH in a 20 mL vial with a magnetic stir bar, and the hydrolysis was performed at room temperature for 2.5 hours until all the ligand was dissolved.

[0215] NaHCO3 1M Solution Add 0.786 g of sodium bicarbonate to 25 mL of distilled water and stir until all the bicarbonate is dissolved.

[0216] Preparation of DVS-activated disks

[0217] The 12DVS activated disks prepared as in Example 2 were placed in a holder and washed 4 times with 500 mL of water for 20 minutes to remove the 20% ethanol storage solution.

[0218] fixed

[0219] The hydrolyzed ligand solution was transferred to a beaker and the vial was repeatedly rinsed with bicarbonate solution to remove as much as possible from the vial. The pH was measured to be 9.94. Half of the amount was poured into a beaker and the pH was adjusted to 11.8 using 50% NaOH. The remaining half was adjusted to pH 8.13 with concentrated hydrochloric acid. The washed DVS-activated nanofiber discs were placed in a 6-well plate using tweezers.

[0220] A: 3 mL ligand solution, pH 11.8, in triplicate

[0221] B: 1.5 mL ligand solution + 1.5 mL distilled water, pH 11.8, in triplicate

[0222] C: 3 mL ligand solution, pH 8.1, in triplicate

[0223] D: 1.5 mL ligand solution + 1.5 mL distilled water, pH 8.1, in triplicate

[0224] The plates were wrapped in parafilm and placed on a shaker at room temperature and 90 rpm overnight (17.2 h). The A and B disks turned yellow immediately, while pH 8.1 did not seem to be affected.

[0225] All disks had a certain yellow color, pH 8.1 was less than pH 11.8. The disks were removed from the wells and placed in a washing apparatus using a plastic mesh in a 1 L beaker and washed with 6 x 800 mL of water. The pH of the solution was controlled to be about 7. The disks were placed in a 6-well plate and stored in water in a refrigerator.

[0226] The disks were loaded with nickel ions and evaluated a) with pure his-tagged green fluorescent protein (GFP-His) (0.3 mg / ml), b) with E. coli supernatant spiked with GFP-His, and c) with monoclonal antibody CHO cell culture supernatant spiked with GFP-His.

[0227] a) Pure GFP-His

[0228] A 10 ml sample of GFP-His solution was loaded onto a disc placed in a syringe filter device. Experiments were performed at four different flow rates (1, 5, 10 and 20 ml / min). Table 4 shows the yield data for GFP-His eluted with imidazole.

[0229] Table 4. GFP-His solution

[0230] Flow rate (ml / min) area Yield (mg) Collected volume (ml) Concentration (mg / ml) Yield (% of loading) 1 2447 2.913 5.7 0.512 97 5 1762 2.098 6.0 0.349 70 10 1294 1.540 6.0 0.257 51 20 1052 1.253 6.0 0.208 40 1 (repeat) 2342 2.788 6.0 0.465 93

[0231] b) E. coli supernatant spiked with GFP-His

[0232] GFP-His was added to the E. coli culture to give a GFP-His concentration of 100 μg / ml and the culture was ultracentrifuged at 20 000 rpm for 20 minutes. 50 ml was loaded onto the disk in the syringe filter device at a flow rate of 10 ml / min and GFP-His was eluted with imidazole buffer. The yield data are shown in Table 5.

[0233] Table 5. E. coli supernatant spiked with GFP-His

[0234] Flow rate (ml / min) area Yield (mg) Collected volume (ml) Concentration (mg / ml) Yield (% of loading) 10 4121 2.45 12 0.206 49

[0235] c) CHO cell culture supernatant spiked with GFP-His

[0236] 500 ml of CHO cell supernatant was ultracentrifuged at 20 000 rpm for 30 minutes and spiked with 6.4 μg / ml GFP-His. 500 ml was then loaded onto the disk in a syringe filter device at a flow rate of 10 ml / min and GFP-His was eluted with imidazole buffer. The yield data are shown in Table 6.

[0237] Table 6. CHO cell supernatant spiked with GFP-His

[0238] Flow rate (ml / min) area Yield (mg) Collected volume (ml) Concentration (mg / ml) Yield (% of loading) 10 869 2.5 5.5 0.466 78

[0239] For CHO cell culture experiments, time and buffer consumption were:

[0240] Load 500 ml at 10 ml / min - 50 minutes Wash 50 column volumes at 10 ml / min - 5 minutes Elute 15 column volumes at 5 ml / min - 5 minutes

[0241] Total: 1 hour, 65ml

[0242] For comparison, the results using a packed bed column (HisTrap excel 5ml, Cytiva) were:

[0243] Load 500 ml at 5 ml / min - 1 hour 40 minutes Wash 30 column volumes at 5 ml / min - 30 minutes Elute 10 column volumes at 5 ml / min - 10 minutes

[0244] Total: 2 hours 20 minutes, 200 ml

[0245] Analytical methods

[0246] Determine dynamic binding capacity

[0247] Pass the load material through The selected functionalized nanofiber disc contained in the holder on the Pure system (GE Healthcare). The material was loaded at a determined membrane volume / minute flow rate (mV / min) until the concentration after the holder outlet exceeded 10% of the load concentration determined by the UV flow cell. The total amount of protein loaded onto the disc at 10% penetration was determined by chromatographic analysis in the Unicorn software (GE Healthcare) taking into account the dead volume of the system and the holder device. For anion exchange materials, the load material was 1 mg / mL BSA in 10 mM Tris (pH 8). For cation exchange materials, the load material was 1 mg / mL lysozyme in sodium acetate (pH 4.7).

[0248] Determine the flow resistance

[0249] use The pressure drop (ΔP) across the selected functionalized nanofiber material was determined using a Pure system (GE Healthcare). 10 mM Tris (pH 8) buffer was passed through the functionalized nanofiber disk contained within the holder. The flow rate at which the Δ column pressure (ΔP) equaled 0.5 MPa was recorded.

[0250] Pore ​​size measurement by capillary flow analysis

[0251] The equipment used is POROLUX TM 100 porometer (IB-FT GmbH, Berlin, Germany), and the method is given in Table 7. Further details on the measuring principle can be found on the manufacturer's website http: / / www.ib-ft.com / measurement_principle.html.

[0252] The three pore sizes obtained from the measurements are the minimum pore size, the mean flow pore (MFP) pore size, and the bubble point pore size (maximum pore size).

[0253] Table 7: Capillary Flow Porosimetry

[0254]

[0255] The results of capillary flow porosimetry and an estimate of the average diameter of the nanofibers from the SEM images are shown in Table 8. It can be seen that the presence of the grafted polymer in the Glycidol Q and Glycidol DVS Protein A samples does not affect the overall structure of the fiber network, i.e., the grafted coating is conformal and very thin. If too much grafted polymer is introduced, polymer material may form between the nanofibers, adversely affecting the flow rate performance of the material.

[0256] Table 8 Pore size and nanofiber diameter

[0257]

[0258] This written description uses examples to disclose the invention, including the best mode, and also to enable any person skilled in the art to practice the invention, including making and using any device or system and performing any combined method. The patentable scope of the invention is defined by the claims, and may include other examples that occur to those skilled in the art. Such other examples are intended to be within the scope of the claims if they have structural elements that do not differ from the literal language of the claims, or if they include equivalent structural elements that are not substantially different from the literal language of the claims. All patents and patent applications mentioned in the text are incorporated herein by reference in their entirety, as if individually incorporated.

Claims

1. A separation matrix comprising a plurality of multimodal ligands covalently coupled to a support, wherein the support is a membrane comprising non-woven polymeric fibers, and wherein the ligands are capable of interacting with a target biomacromolecule, wherein the multimodal ligands comprise multimodal cation exchange ligands, wherein the multimodal cation exchange ligands comprise copolymer chains comprising units derived from a) a first monomer of the structure CH2═CH-L4-X1, wherein L4 is a covalent bond or an alkyl ether or hydroxy-substituted alkyl ether chain containing 2 to 6 carbon atoms, and X1 is a sulfonate or phosphonate group, and b) a second uncharged vinyl amide monomer.

2. The separation matrix of claim 1, wherein the polymer fibers are cellulose fibers.

3. The separation matrix of claim 1 or 2, wherein the polymer fibers are saponified or partially saponified cellulose acetate fibers.

4. The separation matrix of claim 1 or 2, wherein the polymer fibers are partially fused together to form a plurality of fiber-fiber fusion points.

5. The separation matrix of claim 1 or 2, wherein the membrane comprises a plurality of nonwoven fiber layers, and wherein the layers are partially fused together.

6. The separation matrix of claim 1 or 2, wherein the polymer fibers have a diameter of 100-800 nm.

7. The separation matrix of claim 1 or 2, wherein the polymer fibers have a diameter of 100-600 nm.

8. The separation matrix of claim 4, further comprising a grafted polymer coating covering the polymer fibers and optionally the fiber-fiber fusion points, and wherein the multimodal ligand is covalently coupled to the grafted polymer coating.

9. The separation matrix of claim 1 or 2, further comprising a plurality of grafted polymer molecules covalently tethered to the polymer fibers, and wherein at least a portion of the multimodal ligands are covalently coupled to the grafted polymer molecules.

10. The separation matrix of claim 9, wherein the grafted polymer molecules are polyglycidol polymer molecules or polyglycidol copolymer molecules.

11. The separation matrix of claim 8, wherein the polymer fibers having the grafted polymer coating have a diameter of 100-1000 nm.

12. The separation matrix of claim 8, wherein the polymer fibers having the grafted polymer coating have a diameter of 100-700 nm.

13. The separation matrix of claim 8, wherein the polymer fibers having the grafted polymer coating have a diameter of 200-700 nm.

14. The separation matrix of claim 9 or 10, wherein the polymer fibers having the grafted polymer molecules have a diameter of 100-1000 nm.

15. The separation matrix of claim 9 or 10, wherein the polymer fibers having the grafted polymer molecules have a diameter of 100-700 nm.

16. The separation matrix of claim 9 or 10, wherein the polymer fibers having the grafted polymer molecules have a diameter of 200-700 nm.

17. The separation matrix according to claim 1 or 2, which has an average pore size of 200-800 nm.

18. The separation matrix according to claim 1 or 2, which has a bubble point pore size of 0.9-1.2 μm.

19. The separation matrix according to claim 1 or 2, which has a bubble point pore size of 1.0-1.2 μm.

20. The separation matrix according to claim 1 or 2, wherein the minimum pore size is 0.2-0.4 μm.

21. The separation matrix according to claim 1 or 2, which has a mean flow pore (MFP) diameter of 0.3-0.5 μm.

22. The separation matrix according to claim 1 or 2, which has a pore volume fraction of 50-90%.

23. The separation matrix of claim 1 or 2, which has a ligand density of 100-2000 μmol ligand / g dry separation matrix.

24. The separation matrix of claim 1 or 2, wherein the pressure drop across the separation matrix is ​​less than 1 MPa / mm bed height when an aqueous liquid phase with a viscosity of less than 1.2 mPas passes through the matrix having a thickness of 0.05-10 mm at a flow rate between 1-640 medium volumes / min.

25. The separation matrix of claim 1 or 2, wherein the pressure drop across the separation matrix is ​​less than 2 MPa when an aqueous liquid phase having a viscosity of less than 1.2 mPas passes through the matrix having a thickness of 0.05-10 mm at a flow rate between 1-640 medium volumes / min.

26. The separation matrix of claim 1 or 2, wherein when an aqueous buffer of pH 5-8 is passed through the separation matrix with a residence time of 0.4 s, the pressure drop across the separation matrix changes by less than 0.07 MPa / mm bed height when the conductivity of the buffer changes within the interval of 3-90 mS / cm.

27. The separation matrix of claim 8, wherein the grafted polymer coating comprises polymer molecules single-point covalently tethered to polymer nanofibers.

28. The separation matrix of claim 9 or 10, wherein the grafted polymer molecules comprise polymer molecules single-point covalently tethered to polymer nanofibers.

29. The separation matrix of claim 8, wherein the grafted polymer coating comprises branched polymer molecules.

30. The separation matrix of claim 9 or 10, wherein the grafted polymer molecules comprise branched polymer molecules.

31. The separation matrix of claim 8, wherein the grafted polymer coating comprises glycidol monomer residues.

32. The separation matrix of claim 9 or 10, wherein the grafted polymer molecules comprise glycidol monomer residues.

33. The separation matrix of claim 8, wherein the grafted polymer coating comprises divinyl sulfone monomer residues.

34. The separation matrix of claim 9 or 10, wherein the grafted polymer molecules comprise divinyl sulfone monomer residues.

35. The separation matrix of claim 1 or 2, wherein the multimodal ligand comprises a multimodal anion exchange ligand.

36. The separation matrix of claim 35, wherein the multimodal anion exchange ligand comprises a ligand having the structure R1-L1-N(R3)-L2-R2, which is coupled to the support via the nitrogen, wherein: R1 is a five-membered or six-membered substituted or unsubstituted aromatic or aliphatic ring structure, a hydroxyethyl group or a C1-C4 alkyl group; L1 is a methylene group or a covalent bond; R2 is a five-membered or six-membered substituted or unsubstituted aromatic or aliphatic ring structure; L2 is a methylene group or a covalent bond; R3 is methyl.

37. The separation matrix of claim 35, wherein the multimodal anion exchange ligand comprises an N-benzyl-N-methylethanolamine ligand coupled to the support via the nitrogen.

38. The separation matrix of claim 1, wherein the multimodal cation exchange ligand comprises a ligand having the structure S-R4(COOH)-N(H)-C(O)-R5 which is coupled to the support via the sulfur, wherein: R4 is C2-C6 alkylene; and R5 is a five-membered or six-membered substituted or unsubstituted aromatic or aliphatic ring structure.

39. The separation matrix of claim 38, wherein the multimodal cation exchange ligand comprises a ligand having the structure It is coupled to the support via the sulfur.

40. The separation matrix of claim 1, wherein the multimodal cation exchange ligand comprises vinyl sulfonate-co-N-vinyl pyrrolidone copolymer chains.

41. The separation matrix of claim 1 or 2, wherein the multimodal ligand comprises a metal chelating ligand.

42. The separation matrix of claim 41, wherein the metal chelating ligand comprises a ligand having at least three carboxyl groups and at least one tertiary amine.

43. The separation matrix of claim 41, wherein the metal chelating ligand comprises a ligand having at least three carboxyl groups and at least two tertiary amines.

44. The separation matrix of claim 41, wherein the metal chelating ligand comprises a ligand having the structure It is coupled to the support via the amide nitrogen.

45. The separation matrix of claim 41, wherein the metal chelating ligand comprises a ligand having the structure It is coupled to the support via the sulfur.

46. ​​The separation matrix of claim 41, further comprising a transition metal ion bound to the ligand.

47. The separation matrix of claim 41, further comprising Ni bound to the ligand 2+ ion.

48. A method for recovering a purified biomacromolecule from a load fluid comprising one or more impurities, comprising the steps of: a) passing the load fluid through the separation matrix according to claim 1 or 2; and b) recovering said purified biomacromolecule in said matrix effluent during said load cycle and optionally during any substantially isocratic wash.

49. The method of claim 48, wherein the biomacromolecule is a protein.

50. The method of claim 48, wherein the biomacromolecule is an immunoglobulin.

51. The method of claim 48 or 49, wherein the separation matrix is ​​as defined in claim 33.

52. A method for recovering a purified biomacromolecule from a load fluid comprising one or more impurities, comprising the steps of: a) passing the load fluid through the separation matrix according to claim 1 or 2; b) optionally passing a wash fluid through the separation matrix; c) passing an eluent through the separation matrix; d) recovering the purified biomacromolecule in the eluate after passing through the separation matrix; and e) passing a regeneration fluid through the separation matrix.

53. The method of claim 52, wherein the biomacromolecule is a protein.

54. The method of claim 52, wherein the biomacromolecule is an immunoglobulin.

55. The method of any one of claims 52-54, wherein the separation matrix is ​​as defined in any one of claims 37-45.

56. The method of any one of claims 52-54, wherein steps a)-e) are repeated at least 10 times.

57. The method of any one of claims 52-54, wherein the total cycle time of the sequence of steps a)-e) is less than 5 minutes.

58. The method of claim 48 or 52, wherein the load fluid is the eluate from a previous affinity chromatography step.

59. The method of claim 58, wherein the biomacromolecule is an immunoglobulin and the affinity chromatography step is a Protein A step.

60. The method of claim 58 or 59, wherein the affinity chromatography step is performed on a separation matrix comprising a plurality of affinity ligands covalently coupled to a support membrane comprising nonwoven polymeric fibers.

61. The method of claim 60, wherein the affinity ligand is a Protein A ligand.

62. The method of any one of claims 52-54, wherein the biomacromolecule is a protein comprising a polyhistidine tag and the separation matrix is ​​as defined in claim 46.

Citation Information

Patent Citations

  • Mixed mode ligands

    US20150258539A1

  • Multimodal Anion Exchange Matrices

    US20150299248A1

  • Chromatography medium

    US20160288089A1

  • Packing material for liquid chromatography and process for separation and purification of biopolymer by means of the packing material

    US8530698B2

  • Anionic exchange-hydrophobic mixed mode

    US9669402B2